Clinical Trial Update: Long-Term Effects of Infliximab in the Treatment of Moderate to Severe Psoriasis [Extension of Study P04271, NCT00251641] (P04563) [Phase 3]

View source ↗

Summary

Phase 3 extension study assesses long-term effects of infliximab in moderate-to-severe psoriasis; results were posted in 2010 and the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Remicade (infliximab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Psoriasis | Phase 3 | Status: TERMINATED | Results posted: 2010-11-19